-

MedX Issues Shares Related to Debt Settlement Agreement

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX”) (TSX-V:MDX) is pleased to announce that effective December 22, 2020, it closed the debt settlement announced in its Press Release dated December 22, 2020, pursuant to which it settled $65,000 of debt owed to an arm’s length professional adviser by issuance of 500,000 common shares. The shares issued on this debt settlement will be restricted from trading for four months from the date of issue.

About MedX

MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Turkey and Brazil. MedX also designs, manufactures and distributes quality photobiomodulation therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This Media Release may contain forward-looking statements, which reflect the Company’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties.

Contacts

Rob von der Porten, Chairman and Acting CEO
MedX Health Corp
vonderporten@medxhealth.com

Industry:

MedX Health Corp.

TSX VENTURE:MDX
Release Versions
English

Contacts

Rob von der Porten, Chairman and Acting CEO
MedX Health Corp
vonderporten@medxhealth.com

More News From MedX Health Corp.

MedX Announces Non-Brokered Private Placement of Series IV Convertible Loan Notes

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that it is proposing a non-brokered Private Placement to accredited investors of up to $5 million by issuance of up to 100 Convertible Loan Notes, each with a face value of $50,000 (“Series IV Notes”). The Series IV Notes will bear interest at 6% per year, payable Quarterly, and will mature on December 31, 2028 (the “Maturity Date”). The Series IV Notes may be converted, at the...

MedX Health 2025 YEAR REVIEW

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (TSXV: MDX) (“MedX” or the “Company”) is a data-driven health analytics business underpinned by proprietary intellectual property and regulated medical technologies. MedX’s platform generates and analyses high-fidelity skin health data using patented imaging, Teledermatology, and Photobiomodulation systems, creating a growing, defensible data asset and IP moat. MedX operates as an ISO 13485–certified medical device manufacturer and mainta...

MedX Announces Final Closing of Non-Brokered Private Placement

MISSISSAUGA, Ontario--(BUSINESS WIRE)--MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) is pleased to announce that, further to its Press Release dated October 6, 2025, announcing an Initial Closing, it has completed final Closings of the Non-brokered Private Placement to accredited investors originally announced in its Press Release dated July 25, 2025. The Final Closings comprised the issuance of 19,106,666 Units (as described below) and raised cash proceeds of $1,433,000. Securities...
Back to Newsroom